S.Korea Himart plans to raise about $500 mln in IPO

SEOUL, July 29 (Reuters) – Himart, South Korea’s biggest
electronics retailer, plans to raise about 600 billion won
($506.3 million) in a 2011 initial public offering, a Himart
official said.

Himart has chosen Daewoo Securities to manage the IPO, the
proceeds of which are likely to be used to pay off debts owed by
its parent firm Eugene Corp (023410.KQ), the official, who
declined to be named because of the sensitivity of the issue,
said.

Himart, founded in 1987, operates 281 stores in the country.
In its 2009 financial year the company had a a net loss of 37.2
billion won.

Eugene Corp has an 80 percent stake in Himart. Himart CEO Sun
Jong-koo has a 19 percent shareholding, a March regulatory filing
showed.

For a factbox on South Korea’s IPO market, click on
[ID:nTOE62U02Z]

China IPOs seen hitting record high in 2010-PwC

July 5 (Reuters) – Chinese companies may raise a record 500 billion yuan ($73.86 billion) via IPOs this year after a record first half as companies race to tap the stock market for funds, PricewaterhouseCoopers (PwC) said on Monday.

The first-half saw 176 IPOs raising as much as 212.7 billion yuan as compared to no listings in the year-ago period, PwC said.

PwC, which raised its full-year projection from 320 billion yuan previously, expected the number of new listings in China to reach 300 this year, including 25 listings in Shanghai and 275 on the Shenzhen exchange.

Chinese companies raised a total 187.9 billion yuan from the IPO market for the whole of 2009, it said.

“China’s economic growth is expected to continue in the second half of the year. Unless some negative factors emerge, IPOs in Shanghai and Shenzhen will maintain the momentum and are likely to reach historical heights this year,” Charles Feng, PwC Beijing lead partner, told reporters.

China will likely see the world’s second biggest IPO this month when Agricultural Bank of China [ABC.UL], the country’s third-biggest lender by assets, completes its giant dual-lising in Shanghai and Hong Kong.

AgBank’s IPO could raise up to $20.2 billion, excluding a greenshoe, or overallotment option, just a tad smaller than Industrial and Commercial Bank’s (1398.HK) (601398.SS) record $21.9 billion offering in 2006. [ID:nTOE66102S]

AgBank is scheduled to price its IPO later this week.

Other sizeable IPOs expected this year include Industrial Securities’ planned Shanghai listing which will raise roughly $500 million, and Ningbo Port’s planned $1.9 billion offering.

($1=6.770 Yuan)

(Reporting by Soo Ai Peng; Editing by Jonathan Hopfner)

Canada IPO market luring action

(Reuters) – More than a few Canadian companies are ready to go public, though only a handful – some gutsy tech startups with heavy backing — are likely to brave the recent market turbulence and take the final step.

Deals | Small Business | Inflows Outflows

Over the past weeks, initial public stock offerings by Canadian companies have not fared so well, raising less cash than expected in some cases and dropping below their IPO price soon after trading began in others.

Despite months of preparation, sponsors of some issues have pulled or delayed them after prospective buyers proved disinterested.

Even so, investors at last week’s annual Canadian Venture Capital and Private Equity Association meeting in Ottawa were upbeat about the health of the IPO market. Most of those interviewed see activity picking up soon as confidence returns from its nadir during the global financial crisis.

“I think we should expect to see a lot more (IPOs) through the balance of the year, unless there’s some other major new (market) event,” said Rick Nathan, managing director at Kensington Capital Partners, a Toronto-based firm with some C$500 million in capital under management.

The names bandied about at the CVCA meeting, the largest annual industry gathering of its kind in Canada, were mostly in technology fields.

At least three were on most everybody’s lips as key IPO candidates: ViXs, a Toronto-based semiconductor company that makes advanced video processing products; BelAir Networks, an Ottawa-based wi-fi solutions company; and Smart Technologies, a Calgary-based maker of electronic whiteboards backed by the venture capital arm of Intel Corp (INTC.O).

Smart Technologies has been pegged as an IPO candidate for the past year, and a story in Canada’s Globe and Mail said on Friday an IPO could value the company at some C$2 billion, with the founders keeping a third of the company.

At the conference last week, the head of one venture capital firm said the IPO could raise some C$400 million.

ViXs is also seen as ready for IPO, with investors pointing at major backing in Canada and the United States as evidence of a worthy pedigree.

One investor with knowledge of the company and its managers said ViXs would be more likely to look at a U.S. listing on the Nasdaq due to the nature of its backers.

In Canada, ViXs has the backing of Celtic House Venture Partners, one of the country’s most active investors in private information and communications technology, with C$315 million ($297 million) in assets under management.

It also has the backing of NEA, a U.S.-based firm with $11 billion in assets under management and which in the past 30 years has invested in 165 companies that have gone public.

BelAir Networks is backed by Export Development Canada, a self-financed crown corporation that helps finance Canadian exporters, and by Panorama Capital, a Silicon Valley-based fund with Canadian managers.

The company, which provides WLAN market services globally, was founded in 2001 and has customers that include AT&T and Cablevision.

On its website, it also says it is backed by investment from Comcast Interactive Capital, T-Mobile Venture Fund and leading venture capital firms including Trilogy Equity Partners.

But what may stop any of these companies going forward with an IPO is a market that’s still subject to turbulence, as the recent European debt crisis proves.

Case in point is Porter Airlines, who’s bold plan to go public in April appears to be fizzling, with institutional investors less than excited about buying into the opportunity.

Institutions like pension fund managers are vital to any IPO deal because they normally account for purchase of about 75 percent of the issue.

The Globe and Mail reported Friday that Porter Aviation Holdings Inc was chopping the stock price on its C$120 million public offering, to about C$5.50 a share from between C$6 and C$7 a share. The newspaper cited “an industry official familiar with the IPO” as its source.

“Right now a lot of these IPOs are on hold because of the Europe fiasco,” said Rob Chaplinsky, a U.S.-based technology investor and the managing director of Bridgescale Partners, a Silicon Valley-based investor in technology companies.

So far this year initial public offerings in Canada have raised some C$2.84 billion, including over-allotments, compared with C$1.97 billion in all of 2009 and some C$700 million in 2008, according to Thomson Reuters data.

(Reporting by Pav Jordan, Editing by Frank McGurty)

DEALTALK-Bay St says life sciences fare better in U.S.

TORONTO, April 9 (Reuters) – Canadian life sciences companies that need to raise cash in capital markets are best served going south of the border for their financing needs, Bay Street specialty bankers said.

“The IPO market in Canada is nonexistent for life sciences,” said Shameze Rampertab, a partner at Loewen, Ondaatje, McCutcheon & Company in Toronto.

So began a recent panel discussion by bankers in Toronto’s financial district, where life sciences players bemoaned the market’s lack of interest in financing them nearly three years after the last life sciences initial public offering in Canada in November 2007.

“The whole world changed for this sector in the fall of 2007, when the door slammed shut,” said Wayne Schnarr, a healthcare consultant for TMX Equicom and the moderator for a panel entitled The View from Bay Street at BioFinance 2010, which took place April 6-8.

Canadian market interest in life sciences companies has been sapped by poor drug trial results, the global financial crisis and an investing public besotted with mining and energy stocks.

Canadian-listed companies raised more than C$64 billion in 2009, but only C$366 million of that was directed towards Canadian biotechs, the lowest amount in a decade and a tiny fraction of the record $55 billion raised by the U.S. biotech sector last year in partnerships and financings.

“We spend 90 percent of our time marketing in the United States,” said Andrew Smitiuch, managing director for investment banking at Dundee Capital Markets in Toronto.

In fact, the three-day meeting in Toronto had a decidedly U.S.-flavor to it, including a luncheon that featured seven U.S. bankers at the head table, several of whom urged Canadian biotechs to choose a Nasdaq listing over a Canadian one if they hoped to survive.

U.S. investors are hungry for biotech, eager to invest early in the next great wonder drug or medical device.

“In my 10 years in venture capital I’ve never seen a more opportune time to invest in life sciences than over the last year,” said Rod Altman, a doctor and senior partner at U.S. private equity firm CMEA Capital, which has about $1.3 billion of investments under management.

CANADIAN COMPANY BREAKTHROUGHS

Pools of capital are smaller in Canada and most investment funds are generalists, panelists said, adding that as capital starts to flow back into the biotech sector as economies recover from the crisis, Canadian investors are largely absent.

Bankers said Canadians are also less patient than their U.S. counterparts, demanding quicker returns.

Life science companies finance to events – going to market as they hit major milestones in the development of new drugs or technologies.

Experts said Canadian investors may want to take another look at biotech stocks in coming months, when three homegrown companies will see treatments go before U.S. or European regulators for approval for commercial production.

Theratechnologies (TH.TO), a Montreal-based company, is awaiting approval of tesamorelin, for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

Cardiome Pharma Corp (COM.TO) hopes to see vernakalant, which is used for the treatment of atrial fibrillation, receive regulatory approval.

And Isotechnika Pharma Inc (ISA.TO) is also hoping for a regulatory approval in coming months for its drug voclosporin, under the proposed brand name LUVENIQ. Voclosporin is proposed for the treatment of non-infectious uveitis involving the posterior segment of the eye, a leading cause of vision loss and long-term disability and the fourth leading cause of legal blindness in the industrialized world.

“Lets hope they make it so we can trumpet their success to Canadian investors,” said Equicom’s Schnarr.

($1=$1.006 Canadian) (Reporting by Pav Jordan; editing by Peter Galloway)

Skype IPO Worth $3 Billion? Dream On

We love our friends over at Business Insider (which until a few months ago was known as Silicon Alley Insider). But occasionally we wonder if the pressure of filing 85 items a day clouds the judgment of their finger-sore contributors.

On Tuesday evening, BI’s Dan Frommer published a post saying that the planned public spinoff of voice-over-Internet-protocol phone provider Skype from eBay (EBAY), announced that afternoon, might be worth as much as $3.1 billion. He based that on a note from an investment banker predicting that Skype might have pre-tax earnings of $156 million in 2010 (an aggressive but not absurd estimate). The banker then multiplied that figure by the not terribly precise range of 10 to 20, and came up with the not terribly precise range of $1.6 billion to $3.1 billion.

Why is that number so laughable? We already know that Skype today is worth nowhere near that much money; eBay would not be taking the IPO route if it could fetch even half of $3 billion for the company that eBay purchased in one of Meg Whitman’s more questionable moments.

But ok, IPOs have been known to get overheated. And even if the IPO market today is about as dead as a shot pirate, it will bounce back some day.

Still, given today’s slump, how can anyone justify the 10-20x multiplier? Certainly not by rational projections of Skype’s future growth. The service boasts some 400 million users, but as Om Malik argued pretty definitively in January, Skype’s growth is clearly flattening. Perhaps most importantly, Skype’s most important selling point is that it’s free between Skype users. If Skype as a standalone company tries to charge users, millions of them will simply switch to a free competitor. The fact is, standalone VOIP companies–even when they are able to charge for their services–don’t have a great track record. Just ask Vonage (VG).

Don’t get me wrong, the eBay plan is smart: Get Skype off the books. But eBay’s wishful thinking about Skype’s value was wrong in 2005; any investment banker arguing it’s worth $3.1 billion today or next year is just as wrong, and ought to be quizzed, not copied.

UPDATE: The New York Times has found an even more credulous analyst to say Skype’s IPO could fetch as much as $4 billion! Hey, why not $10 billion? Doesn’t anyone ever ask these people to define and defend the valuation yardsticks they use? Comparisons to past IPOs have little use since, as the Times at least acknowledges, “public markets [have] not been very receptive to initial offerings” of late.